Author Affiliations1Medical Institute of North-Eastern Federal University n.a. M.K. Ammosov 677016, Yakutsk, Oyunskogo str., 27
2Medical Institute of North-Eastern Federal University n.a. M.K. Ammosov 677016, Yakutsk, Oyunskogo str., 27
3Medical Institute of North-Eastern Federal University n.a. M.K. Ammosov 677016, Yakutsk, Oyunskogo str., 27
4Medical Institute of North-Eastern Federal University n.a. M.K. Ammosov 677016, Yakutsk, Oyunskogo str., 27
The aim of the study was to evaluate the susceptibility to antibiotics of Klebsiella pneumoniae isolates in the Republic of Sakha (Yakutia), according to the AMRmap database. Material and methods. Data of online platform AMRmap in 2010–2016 have been used for evaluation of the sensitivity of K. pneumoniae isolates to antibiotics. Results and discussion. K. pneumoniae isolates comprised 35,7 % of all bacterial nosocomial isolates (n = 195) and 30,1 % of community-acquired isolates (n = 382) respectively. Most of the isolates were insusceptible to common antibiotics: aminoglycosides (gentamicin, tobramycin, netilmicin) – 50–78 %; chloramphenicol – 36–43 %, cephalosporins III–V generation (ceftazidime, cefotaxime, zepefin, ceftarolin) – 83–100 %, penicillin drugs with inhibitor of beta-lactamases (ticarcillin-clavulanate, amoxicillin-clavulanate) – 83–98 % monobactams (aztreonam) – 87–95 %, semi-synthetic penicillins of broad spectrum of action (ampicillin) – 100 %, sulfonamides (trimethoprim-sulfamethoxazole) – 53–76 %, fluoroquinolones (ciprofloxacin) – 77 %. At present the next preparations can be effective against K. pneumonia: amikacin (sensitivity 96–100 %), ceftazidime-avibactam (95–97 %), tigecycline (97–100 %), carbapenems (87–97 %), in some cases, phosphomycin (77 %) and piperacillin-tazobactam (64–71 %). Conclusion. The spectrum of drugs for the treatment of infections caused by K. pneumoniae is extremely limited. The further spread of resistance to carbapenems poses a threat of ineffectiveness in the treatment of severe infections. In these conditions, measures are needed to limit the unjustified use of carbapenems. The indicators of resistance of K. pneumoniae to antibiotics should be taken into account not only for the effective treatment of patients, but also for optimizing the costs of regional health care, for example when planning procurement of medicines for hospitals
Albiger B., Glasner C., Struelens M., Grundmann H., Monnet D., the European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries. Euro Surveill. 2015. 20. (45). pii 30062.
AMRmap. [Online]. 2018. Available at: http://map.antibiotic.ru/ (accessed July 20, 2018).
Antimicrobial resistance: global report on surveillance, 2014. World Health Organization. 2014. [Online]. April, 2014. Available at: http://www.who.int/drugresistance/documents/surveillancereport/en/ (accessed 2018 July 20).
Central Asian and Eastern European Surveillance of Antimicrobial Resistance. Annual report 2016. WHO. Available at: http://www.euro.who.int/en/publications/abstracts/central-asian-and-eastern-european-surveillance-of-antimicrobial-resistance.-annual-report-2016 (accessed July 20, 2018).
Chung P.Y. The emerging problems of Klebsiella pneumoniae infections: carbapenem resistance and biofilm formation. FEMS Microbiol. Lett. 2016. 363. (20). 1–6.
Global antimicrobial resistance surveillance system (GLASS) report: early implementation 2016-2017. World Health Organization. 2017. Available at: http://www.who.int/glass/resources/publications/early-implementation-report/en/ (accessed July 20, 2018).
Kidd T.J, Mills G., Sá-Pessoa J., Dumigan A., Frank Ch.G, Insua J.L, Ingram R., Hobley L., Bengoechea J.A. A Klebsiella pneumoniae antibiotic resistance mechanism that subdues host defences and promotes virulence. EMBO Mol. Med. 2017. 9. (4). 430–447.
Kuzmenkov A.Yu., Trushin I.V., Avramenko A.A., Eidelshtein M.V., Dekhnich A.V., Kozlov R.S. AMRmap: an online platform for monitoring antibiotic resistance. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya = Clinical microbiology and antimicrobial chemotherapy. 2017. 19. (2). 84–90. [In Russian].
Navon-Venezia S., Kondratyeva K., Carattoli A. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol. Rev. 2017. 41. (3). 252–275.
Sukhorukova М.V., Edelstein М.V., Skleenova Е.Yu., Ivanchik N.V., Timokhova А.V., Sheck Е.А., Dekhnich А.V., Kozlov R.S., the «MARATHON» Study Group. Antimicrobial Resistance of Nosocomial Enterobacteriaceae Isolates in Russia: Results of National Multicenter Surveillance Study «MARATHON» 2011–2012. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya = Clinical microbiology and antimicrobial chemotherapy. 2014. 16 (4). 254–265. [In Russian].
